Rani Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results; Provides Corporate Update
View original at finance.yahoo.comRani Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results; Provides Corporate Update Rani Therapeutics, LLC - Announced up to $1.085 billion collaboration with Chugai Pharmaceutical Co…
What we drew from this source
The claims Via News extracted from this document. We point to the source; we don't replace it.
Throughout 2025, we generated a robust body of preclinical evidence for RT-114 and our oral semaglutide, demonstrating the potential of the RaniPill platform to enable oral delivery of complex incretin-based therapies
60% confidenceWe entered 2026 at an important inflection point, highlighted by the initiation of our Phase 1 study of RT-114, our first orally administered GLP-1/GLP-2 (PG-102) dual agonist delivered via the RaniPill capsule
60% confidenceWith the initiation of our Phase 1 trial of RT-114 in December 2025, we are well positioned to advance our first oral GLP-1/GLP-2 dual agonist into clinical development and continue unlocking the potential of the RaniPill platform across high-value therapeutic areas
60% confidenceRT-116 was well tolerated with no serious adverse events
60% confidenceThe partnership demonstrates RaniPill's potential to convert injectable biologics into oral therapies, improving patient adherence and accessibility
60% confidence